Lobbying disclosures · Lobbying report
SRPT: second_quarter 2026 lobbying report
H.R. 9260 - LHHS Appropriations H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to supply chain Issues related to Section 232
Follow SRPT- Became public
- Jul 20, 2026, 1:40 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 10, 2026, 10:59 AM EST
Why this is connected
Exact legal-name match: Sarepta Therapeutics, Inc. (https://www.sec.gov/Archives/edgar/data/873303/).
Reported lobbying amounts
Expenses: $220,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/944a9a08-7e31-419b-a2c8-ae9e2f1e01ea/","filing_uuid":"944a9a08-7e31-419b-a2c8-ae9e2f1e01ea","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/944a9a08-7e31-419b-a2c8-ae9e2f1e01ea/print/","filing_document_content_type":"text/html","income":null,"expenses":"220000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Unger Skelton","dt_posted":"2026-07-20T13:40:41-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"c/o 28 Liberty Ship Way, Suite 2815","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Sausalito","registrant_state":"CA","registrant_zip":"94965","registrant":{"id":401103510,"url":"https://lda.gov/api/v1/registrants/401103510/","house_registrant_id":null,"name":"SAREPTA THERAPEUTICS, INC.","description":"Biopharmaceutical company","address_1":"c/o 28 Liberty Ship Way, Suite 2815","address_2":null,"address_3":null,"address_4":null,"city":"Sausalito","state":"CA","state_display":"California","zip":"94965","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE UNGER SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-07-23T16:08:48.090815-04:00"},"client":{"id":199232,"url":"https://lda.gov/api/v1/clients/199232/","client_id":12,"name":"SAREPTA THERAPEUTICS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-12-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 9260 - LHHS Appropriations","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.R. 1509 - Accelerating Kids Access to Care Act Patient Access Act Issues related to patient access to treatment","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"National Security Commission on emerging biotechnology policy proposals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to supply chain Issues related to Section 232","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in SRPT
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- May 6, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Apr 14, 2025 · disclosed May 6, 2025
- Aug 21, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Sarepta Therapeutics SRPT
$1K–$15K · Traded Jul 14, 2023 · disclosed Aug 21, 2023 · Joint
- Jul 11, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Jun 13, 2023 · disclosed Jul 11, 2023 · Joint
- May 19, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Sold Sarepta Therapeutics SRPT
$15K–$50K · Traded Apr 10, 2023 · disclosed May 19, 2023
- Apr 20, 2023$1K–$15K
Rep. Josh Gottheimer (D-NJ-5)
Bought Sarepta Therapeutics SRPT
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 20, 2023 · Joint
- Apr 17, 2023$15K–$50K
Rep. Daniel S. Goldman (D-NY-10)
Bought Sarepta Therapeutics SRPT
$15K–$50K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Feb 24, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Sarepta Therapeutics SRPT
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.